Department of Biochemistry, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Tajganj, Agra 282004, India.
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Medical Laboratory Sciences, Division of Research and Development, Lovely Professional University, Phagwara, Punjab 144411, India.
J Glob Antimicrob Resist. 2020 Sep;22:210-214. doi: 10.1016/j.jgar.2020.02.029. Epub 2020 Mar 10.
In the current scenario, the emergence of drug resistance in Mycobacterium tuberculosis is the consequence of the failure of conventional diagnostic and treatment approaches. To combat this global emergence of drug resistance, alternative approaches such as pathogen-centric (use of repurposed drugs, novel analogues of existing anti-TB drugs and novel compounds with a different mechanism of action), host-centric (immunomodulatory agents, therapeutic vaccines, immune and cellular therapies) and nano-based drug/vaccine delivery should be used singly or in combination. Diverse types of nano-carriers have assessed as auspicious diagnostic and drug delivery systems. In this focused review, we have suggested a long-term solution for combating antimicrobial resistance and also an attractive means to increase patient compliance and reduce treatment duration.
在当前的情况下，结核分枝杆菌耐药性的出现是传统诊断和治疗方法失败的结果。为了应对这种全球耐药性的出现，应该单独或联合使用以病原体为中心（使用重新定位的药物、现有抗结核药物的新型类似物和具有不同作用机制的新型化合物）、以宿主为中心（免疫调节剂、治疗性疫苗、免疫和细胞疗法）和基于纳米的药物/疫苗递送等替代方法。多种类型的纳米载体已被评估为有前途的诊断和药物递送系统。在本次重点综述中，我们提出了一个长期解决方案来对抗抗微生物耐药性，同时也为提高患者依从性和缩短治疗时间提供了一个有吸引力的手段。
